Synovus Financial Corp reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 295,637 shares of the company’s stock after selling 3,087 shares during the period. Johnson & Johnson makes up about 0.6% of Synovus Financial Corp’s holdings, making the stock its 29th largest position. Synovus Financial Corp’s holdings in Johnson & Johnson were worth $52,224,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. Lincoln Capital Corp boosted its position in shares of Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC boosted its position in shares of Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after buying an additional 6,154 shares in the last quarter. RFG Advisory LLC boosted its position in shares of Johnson & Johnson by 2.7% in the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares in the last quarter. Willis Investment Counsel boosted its position in shares of Johnson & Johnson by 0.4% in the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after buying an additional 1,358 shares in the last quarter. Finally, Wambolt & Associates LLC boosted its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after buying an additional 355 shares in the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms recently commented on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Guggenheim initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Raymond James cut their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.00.
Insider Buying and Selling
Johnson & Johnson Trading Down 1.3 %
NYSE JNJ opened at $162.87 on Thursday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35. The company has a 50-day moving average of $158.10 and a 200-day moving average of $167.02. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company has a market cap of $424.16 billion, a P/E ratio of 34.07, a P/E/G ratio of 2.78 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.67 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is 94.56%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Starbucks Stock Becomes a Value Play
- Kraft Heinz Recovery Gains Momentum
- Here’s Why AMD’s Weak Guidance Is A Blessing In Disguise
- BP Shares Sold Off After Earnings: Here Is What Upset Markets
- Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
